Condition: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · Non-Hodgkin's Lymphoma Refractory · Non-Hodgkin's Lymphoma, Relapsed · Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic
Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.
This description comes directly from the study's public registry record.
Jan Vydra · +420221977182 · jan.vydra@uhk.cz
Petr Lesny · +420221977629 · petr.lesny@uhkt.cz
Always discuss trial participation with your own doctor first.
| Institute of Hematology and Blood Transfusion, Czech Republic | Prague, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05054257